We've got you covered
We are here to guide you in making tough decisions with your hard earned money. Drop us your details and we will reach you for a free one on one discussion with our experts.
or
Call us on: +917410000494
Cipla Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India, the United States, South Africa, and internationally. The company offers active pharmaceutical ingredients; and formulations in various therapeutic areas, such as MI, angina, heart failure, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, HIV, respiratory, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. It also provides respiratory products, including inhalers and nasal sprays, as well as other dosage forms consists of injectables and biosimilars. Cipla Limited has collaboration with CSIR-Indian Institute of Chemical Technology for the development of medication for the treatment of COVID-19; partnership with Karwa Ltd. for the commercialization of antibody detection kits for COVID-19; partnership with the Premier Medical Corporation Private Limited for the commercialization of the rapid antigen test kits for COVID-19; licensing agreement with Merck & Co., Inc. for the manufacturing and distribution of Molnupiravir, an investigational oral antiviral drug; license agreement with Eli Lilly and Company for the manufacture and commercialization of the drug baricitinib for Covid-19 indication; and collaborations with Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Limited, Emcure Pharmaceuticals Limited, and Torrent Pharmaceuticals Limited for the clinical trial of the investigational oral anti-viral drug Molnupiravir. The company was incorporated in 1935 and is headquartered in Mumbai, India.
TODAY'S HIGH
950
TODAY'S LOW
928.5
52 WEEK HIGH
1083
52 WEEK LOW
850
% of Shares Held by
All Insider
35.31%
% of Shares Held by
Institutions
32.47%
% of Float Held by
Institutions
50.20%
Number of Institutions
Holding Shares
204
MARKET CAP
75158.08 Cr.
ETERPRISE VALUE
73798.87 Cr.
NO. OF SHARES
80.69 Cr.
BOOK VALUE
258.321
DIV. YIELD
5%
DEBT
1055.78 Cr.
GROSS PROFIT
13267.74 Cr.
CASH
4123.45 Cr.
REVENUE
21763.34 Cr.
REVENUE/SHARE
269.799
| Particulars | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|
| Investments | 152.57 Cr. | -1258.63 Cr. | 1176.69 Cr. | -1068.37 Cr. |
| Change To Liabilities | 362.29 Cr. | 203.05 Cr. | 487.28 Cr. | -152.51 Cr. |
| Total cashflows from Investing Activities | -1871.88 Cr. | -2387.18 Cr. | 104.04 Cr. | -1668.68 Cr. |
| Net Borrowings | -1098.33 Cr. | -1167.85 Cr. | -1760.02 Cr. | -60.25 Cr. |
| Total Cash from Financing Activities | -1599.79 Cr. | -1329.90 Cr. | -2948.82 Cr. | -348.72 Cr. |
| Other Liabilities | 0 | 0 | 0 | 0 |
| Total Assets | 7 Lakhs | 5 Lakhs | 11 Lakhs | 12 Lakhs |
| Net Income | 2516.75 Cr. | 2404.87 Cr. | 1546.52 Cr. | 1527.70 Cr. |
| Change in Cash | -132.32 Cr. | 50.91 Cr. | 234.02 Cr. | -345.10 Cr. |
| Effect of Exchange Rate | 13.45 Cr. | 12.79 Cr. | 10.35 Cr. | -18.85 Cr. |
| Total Cash from Operating Activities | 3325.90 Cr. | 3755.20 Cr. | 3068.45 Cr. | 1691.14 Cr. |
| Depreciation | 1051.95 Cr. | 963.81 Cr. | 1056.40 Cr. | 1056.51 Cr. |
| Other Cashflows from Investing Activities | -1358.46 Cr. | -339.76 Cr. | -88.23 Cr. | 82.60 Cr. |
| Dividends Paid | -403.35 Cr. | -403.35 Cr. | -241.77 Cr. | -241.57 Cr. |
| Change to Inventory | -621.11 Cr. | -254.32 Cr. | -331.55 Cr. | 103.84 Cr. |
| Change to Account Receivables | 81.36 Cr. | 422.93 Cr. | 217.26 Cr. | -1014.87 Cr. |
| Other Cashflows from Financing Activities | -98.18 Cr. | -162.10 Cr. | -624.65 Cr. | -47.02 Cr. |
| Change to Net Income | -65.34 Cr. | -24.45 Cr. | 48.99 Cr. | 129.83 Cr. |
| Capital Expenditures | -544.11 Cr. | -629.66 Cr. | -572.77 Cr. | -360.08 Cr. |
| Particulars | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|
| Research Development | None | None | None | None |
| Effect of Accounting Charges | None | None | None | None |
| Income Before Tax | 3480.45 Cr. | 3277.27 Cr. | 2130.72 Cr. | 2061.97 Cr. |
| Minority Interest | 275.69 Cr. | 259.06 Cr. | 294.28 Cr. | 331.97 Cr. |
| Net Income | 3500.83 Cr. | 3265.51 Cr. | 2119.98 Cr. | 2041.26 Cr. |
| Selling General Administrative | 3529.91 Cr. | 4128.12 Cr. | 3869.37 Cr. | 3741.54 Cr. |
| Gross Profit | 13267.74 Cr. | 11615.53 Cr. | 10932.49 Cr. | 10394.71 Cr. |
| Ebit | 3500.83 Cr. | 3265.51 Cr. | 2119.98 Cr. | 2041.26 Cr. |
| Operating Income | 3500.83 Cr. | 3265.51 Cr. | 2119.98 Cr. | 2041.26 Cr. |
| Other Operating Expenses | 5185.05 Cr. | 3218.78 Cr. | 3843.19 Cr. | 3515.08 Cr. |
| Interest Expense | -106.35 Cr. | -152.98 Cr. | -189.23 Cr. | -163.77 Cr. |
| Extraordinary Items | None | None | None | None |
| Non Recurring | None | None | None | None |
| Other Items | None | None | None | None |
| Income Tax Expense | 933.80 Cr. | 888.76 Cr. | 631.20 Cr. | 569.53 Cr. |
| Total Revenue | 21763.34 Cr. | 19121.90 Cr. | 17080.53 Cr. | 16323.23 Cr. |
| Total Operating Expenses | 18262.51 Cr. | 15856.39 Cr. | 14960.55 Cr. | 14281.97 Cr. |
| Cost of Revenue | 8495.60 Cr. | 7506.37 Cr. | 6148.04 Cr. | 5928.52 Cr. |
| Total Other Income Expense Net | -20.38 Cr. | 11.76 Cr. | 10.74 Cr. | 20.71 Cr. |
| Discontinued Operations | None | None | None | None |
| Net Income from Continuous Ops. | 2546.65 Cr. | 2388.51 Cr. | 1499.52 Cr. | 1492.44 Cr. |
| Net Income Applicable to Common Shares | 2516.75 Cr. | 2404.87 Cr. | 1546.52 Cr. | 1527.70 Cr. |
| Particulars | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|
| Intangible Assets | 1702.86 Cr. | 1828.26 Cr. | 1900.07 Cr. | 1908.15 Cr. |
| Capital Surplus | 0 | 1613.31 Cr. | 1602.03 Cr. | 1574.59 Cr. |
| Total Liabilities | 5983.74 Cr. | 6566.30 Cr. | 7605.28 Cr. | 8619.07 Cr. |
| Stock Holder Equity | 20841.69 Cr. | 18326.53 Cr. | 15763 Cr. | 15012.28 Cr. |
| Minority Interest | 275.69 Cr. | 259.06 Cr. | 294.28 Cr. | 331.97 Cr. |
| Other Liabilities | 1923.85 Cr. | 1133.58 Cr. | 986.13 Cr. | 807.31 Cr. |
| Total Assets | 27101.12 Cr. | 25151.89 Cr. | 23662.56 Cr. | 23963.32 Cr. |
| Common Stock | 161.36 Cr. | 161.29 Cr. | 161.25 Cr. | 161.14 Cr. |
| Retained Earnings | 0 | 16681.62 Cr. | 14260.50 Cr. | 13393.93 Cr. |
| Other Liabilities | 496.01 Cr. | 574.11 Cr. | 659.78 Cr. | 1017.49 Cr. |
| Good Will | 3137.93 Cr. | 3007.29 Cr. | 2934 Cr. | 2869.14 Cr. |
| Treasury Stock | 20680.33 Cr. | -129.69 Cr. | -260.78 Cr. | -117.38 Cr. |
| Other Assets | 1585.15 Cr. | 1062.77 Cr. | 996.80 Cr. | 773.58 Cr. |
| Cash | 1928.48 Cr. | 793.29 Cr. | 742.38 Cr. | 508.36 Cr. |
| Current Liabilities | 4913.21 Cr. | 4591.55 Cr. | 4393.14 Cr. | 3771.51 Cr. |
| Long Term Asset Charges | 448.83 Cr. | 314.69 Cr. | 239.77 Cr. | 201.41 Cr. |
| Short Long Term Debt | 407.90 Cr. | 227.78 Cr. | 16.75 Cr. | 0 |
| Other Stockholder Equity | 20680.33 Cr. | -129.69 Cr. | -260.78 Cr. | -117.38 Cr. |
| Property Plant Equipment | 5608.72 Cr. | 5648.86 Cr. | 5673.35 Cr. | 5507.25 Cr. |
| Total Cur. Assets | 14710.83 Cr. | 13181.03 Cr. | 11703.84 Cr. | 12426.63 Cr. |
| Long Term Investments | 355.63 Cr. | 423.68 Cr. | 454.50 Cr. | 478.57 Cr. |
| Net Tangible Assets | 16000.90 Cr. | 13490.98 Cr. | 10928.93 Cr. | 10234.99 Cr. |
| Short Term Investments | 2194.97 Cr. | 670.36 Cr. | 250.08 Cr. | 100.81 Cr. |
| Net Receivables | 3428.01 Cr. | 3619.34 Cr. | 4226.07 Cr. | 4398.82 Cr. |
| Long Term Debt | 416.24 Cr. | 1202.75 Cr. | 2369.28 Cr. | 3830.07 Cr. |
| Inventory | 5350.24 Cr. | 4669.18 Cr. | 4377.60 Cr. | 3964.83 Cr. |
| Accounts Payable | 2508.10 Cr. | 2066.82 Cr. | 2281.81 Cr. | 1947.99 Cr. |
Open a demat account through us and get the account opening charges waived off
open paperless account